Journal: Hepatology Communications

Article Title: NI‐0801, an anti‐chemokine (C‐X‐C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid

doi: 10.1002/hep4.1170

Figure Lengend Snippet: Serum concentration–time profile. (A) NI‐0801 and (B) total (antibody‐bound and free) CXCL10 in patients with PBC (evaluable analysis set) following six intravenous doses of NI‐0801. The solid line represents mean values, circles represent individual values. Empty circles in (A) represent predose NI‐0801 values on dosing days; the LLOQ of the PK assay is indicated by the dotted line. Abbreviation: LLOQ, lower limit of quantification.

Article Snippet: Briefly, samples were added in triplicate to the lower chamber in the presence or absence of exogenously added recombinant human CXCL10 (R&D Systems).

Techniques: Concentration Assay, PK Assay

Journal: Hepatology Communications

Article Title: NI‐0801, an anti‐chemokine (C‐X‐C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid

doi: 10.1002/hep4.1170

Figure Lengend Snippet: CXCL10 chemotactic activity in serum samples of representative NI‐0801‐treated patients with PBC. (A,B) High or (C,D) low NI‐0801 exposure in the absence (empty bars) or presence (solid bars) of 25 nM exogenous CXCL10. Data represent mean cell counts ± SEM. Abbreviations: ND, not detectable; SD, study day.

Article Snippet: Briefly, samples were added in triplicate to the lower chamber in the presence or absence of exogenously added recombinant human CXCL10 (R&D Systems).

Techniques: Activity Assay

Journal: Journal of Neurochemistry

Article Title: Repeated Low‐Level Inflammatory Challenge Leads to Alterations in the TNF ‐ CXCL10 Signalling Pathway in Mouse Cerebral Endothelial Cells In Vitro

doi: 10.1111/jnc.70130

Figure Lengend Snippet: Repeated administration of a low concentration of TNF modifies the expression of genes associated with endothelial cell activation and the TNF‐CXCL10 pathway. qRT‐PCR was performed to quantify expression of the genes indicated in bEnd.3 cells in four treatment groups: Control (PBS), a single low concentration of Tumour necrosis factor (TNF) (0.5 ng/mL) for 1 h, a single cumulative concentration of TNF (2.0 ng/mL) for 1 h or repeated treatment with TNF at a low concentration (0.5 ng/mL) for 1 h on 4 consecutive days. Expression of Intercellular Adhesion Molecule 1 ( Icam1 ) (a), C‐X‐C Motif Chemokine Ligand 10 (Cxcl10) (b), Tumour Necrosis Factor (Tnf) (c), TNF Receptor‐Associated Factor 2 (Traf2) (d), Interferon Gamma (Ifng) (e) and C‐X‐C Chemokine Receptor 3 (Cxcr3) (f) was quantified 4 h and 24 h post final treatment. Data were analysed using one‐way ANOVA, followed by Tukey's post hoc test. Biological replicates ( n = 6) are expressed as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.001. ns = not statistically significant.

Article Snippet: The effects of exogenous CXCL10, a pro‐inflammatory chemokine, were determined by exposing cells to recombinant mouse CXCL10 (R&D Systems; cat. no #466‐CR) or vehicle alone (PBS) for 24 h. For experiments involving repeated inflammatory challenge, cells were plated in 6‐ or 12‐well plates at a seeding density of 1 × 10 5 or 5 × 10 4 cells per well, respectively.

Techniques: Concentration Assay, Expressing, Activation Assay, Quantitative RT-PCR, Control

Journal: Journal of Neurochemistry

Article Title: Repeated Low‐Level Inflammatory Challenge Leads to Alterations in the TNF ‐ CXCL10 Signalling Pathway in Mouse Cerebral Endothelial Cells In Vitro

doi: 10.1111/jnc.70130

Figure Lengend Snippet: Repeated inflammatory challenge with TNF upregulates key proteins within the TNF‐CXCL10 pathway. bEnd.3 cells were exposed to control (phosphate buffered saline; PBS), a single low concentration of Tumour necrosis factor (TNF) (0.5 ng/mL), a single cumulative concentration of TNF (2.0 ng/mL) or repeated treatment with a low TNF concentration (0.5 ng/mL) for 1 h for 4 days. Intercellular Adhesion Molecule 1 (ICAM1) (a), C‐X‐C Motif Chemokine Ligand 10 (CXCL10) (b, c), Signal Transducer and Activator of Transcription 1 (STAT1) (d) and Phosphorylated STAT1 (pSTAT1) (e) expression were evaluated by western blotting at both 4 and 24 h post final treatment. Secreted CXCL10 protein was quantified using ELISA at both time points (c). Blots were run on the same gels and membranes, cut according to molecular weight and probed separately; therefore, the same GAPDH loading control is shown for some of these targets. Data were analysed using one‐way ANOVA, followed by Tukey's post hoc test. Biological replicates ( n = 4) are given as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.001.

Article Snippet: The effects of exogenous CXCL10, a pro‐inflammatory chemokine, were determined by exposing cells to recombinant mouse CXCL10 (R&D Systems; cat. no #466‐CR) or vehicle alone (PBS) for 24 h. For experiments involving repeated inflammatory challenge, cells were plated in 6‐ or 12‐well plates at a seeding density of 1 × 10 5 or 5 × 10 4 cells per well, respectively.

Techniques: Control, Saline, Concentration Assay, Expressing, Western Blot, Enzyme-linked Immunosorbent Assay, Molecular Weight

Journal: Journal of Neurochemistry

Article Title: Repeated Low‐Level Inflammatory Challenge Leads to Alterations in the TNF ‐ CXCL10 Signalling Pathway in Mouse Cerebral Endothelial Cells In Vitro

doi: 10.1111/jnc.70130

Figure Lengend Snippet: CXCL10 influences apoptosis and proliferation of bEnd.3 cells. (a) bEnd.3 cells were treated for 24 h with the indicated C‐X‐C Motif Chemokine Ligand 10 (CXCL10) concentrations and caspase 3/7 activity measured, with percentage apoptosis calculated from the number of fluorescent cells relative to total cell number. (b) Cell nuclei were stained with Hoechst following CXCL10 treatment, and cell number was quantified and normalised to control. (c–h) Cells treated with CXCL10‐targeting small interfering RNA (siRNA) or scrambled control siRNA were repeatedly exposed to Tumour necrosis factor (TNF) (0.5 ng/mL). Gene and protein expression of CXCL10 and ICAM1 was measured using RT‐qPCR and western blotting. (i) Representative light and fluorescent images (10× magnification) of cells treated with either CXCL10‐targeting siRNA or scrambled control siRNA and subsequently exposed to TNF (0.5 ng/mL), showing apoptotic (green) cells. Scale bar = 300 μm. (j) Representative images of Hoechst staining (blue) for quantification of cell number in the same treated cells. Scale bar = 750 μm. (k) The number of apoptotic cells per image was calculated as a percentage of total cell number. (l) The mean cell number was calculated for each treatment group. Data were analysed using one‐way ANOVA, followed by Tukey's post hoc test. Biological replicates ( n = 4–6) are shown as mean ± SD. * p < 0.05, ** p < 0.01 and *** p < 0.001 and **** p < 0.0001.

Article Snippet: The effects of exogenous CXCL10, a pro‐inflammatory chemokine, were determined by exposing cells to recombinant mouse CXCL10 (R&D Systems; cat. no #466‐CR) or vehicle alone (PBS) for 24 h. For experiments involving repeated inflammatory challenge, cells were plated in 6‐ or 12‐well plates at a seeding density of 1 × 10 5 or 5 × 10 4 cells per well, respectively.

Techniques: Activity Assay, Staining, Control, Small Interfering RNA, Expressing, Quantitative RT-PCR, Western Blot